PDAC - Pancreatic Ductal Adenocarcinoma trials recruiting in Arizona

All PDAC - Pancreatic Ductal Adenocarcinoma trials nationally

Cities in Arizona

Recruiting trials in Arizona

• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT07252232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  NCT06922591 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale